Cord Blood News 8.40 October 13, 2016 | |
| |
TOP STORYInvestigators studied the relation between anti-thymocyte globulin (ATG) exposure, immune reconstitution and clinical outcomes. All pediatric patients receiving a first cord blood transplantation between 2004-2015 at the University Medical Center Utrecht were included. [Blood] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Exosomes Derived from MSCs Ameliorate Retinal Laser Injury Partially by Inhibition of MCP-1 Scientists intravitreally injected mesenchymal stem cells (MSCs) derived from either mouse adipose tissue or human umbilical cord, and their exosomes to observe and compare their functions in a mouse model of laser-induced retinal injury. [Sci Rep] Full Article Mesenchymal stem cells (MSCs) derived from bone marrow, adipose and umbilical cord that were infected with Newcastle disease virus (NDV) delivered the virus to co-cultured glioma cells and glioma stem cells. Conditioned medium of NDV-infected MSCs induced higher level of apoptosis in the tumor cells compared with the apoptosis induced by their direct infection with similar virus titers. [Stem Cell Res Ther] Full Article The DNAm profile of cord blood derived nucleated red blood cell (nRBCs) was compared with B cells, CD4 and CD8 T cells, natural killer cells, granulocytes, monocytes and placenta. nRBCs and placenta had similarly low array-wide DNAm compared with white blood cells, but their patterns of hypomethylation differed at biologically relevant subsets of the array. [Epigenomics] Abstract Researchers analyzed the protein expression spectrum of the cortical peri-infarction region after ischemic stroke followed by treatment with human umbilical cord mesenchymal stem cells (hUC-MSCs), and found 16 proteins expressed differentially between groups treated with or without hUC-MSCs. [Aging Dis] Full Article Human Wharton’s jelly–derived mesenchymal stromal cells (MSCs) derived from three anatomical segments of the umbilical cord were compared. [Cytotherapy] Abstract The authors evaluated the effects of using different nuclear donor cell types in two successive experiments: I) induced pluripotent stem cells (iPSCs) vs. adult fibroblasts (AF) fused to ooplasts injected with the pluripotency-inducing genes OCT4, SOX2, MYC and KLF4, vs. AF alone as controls; II) umbilical cord-derived mesenchymal stromal cells vs. fetal fibroblasts derived from an unborn cloned fetus vs. AF from the original individual. [PLoS One] Full Article The intracerebral and intravenous administration of umbilical cord-derived mesenchymal stem cells (UC-MSCs) both resulted in significant improvement in neurological function and decrease in injury volume of intracerebral hemorrhage (ICH) rats. Transplanted UC-MSCs were chemotactic in vivo and showed a predominant distribution around the ICH region. [Med Sci Monit] Abstract | |
| |
REVIEWSPeripheral Blood Mononuclear Cell Secretome for Tissue Repair The authors describe the benefits of choosing peripheral blood mononuclear cells (PBMCs) instead of stem cells in regenerative medicine and characterize the factors released from apoptotic PBMCs. They also discuss pre-clinical studies with apoptotic cell-based therapies and regulatory issues that have to be considered when conducting clinical trials using cell secretome-based products. [Apoptosis] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSGamida Cell Receives FDA Breakthrough Therapy Designation for NiCord® Gamida Cell announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the company’s lead product candidate, NiCord®, in development as a novel graft modality for bone marrow transplantation in patients with high risk hematological malignancies such as leukemia and lymphoma. [Gamida Cell] Press Release The Tisch Cancer Institute Receives a $10 Million Grant to Study Acute Graft-versus-Host Disease Physician-scientists at The Tisch Cancer Institute have been awarded $10 million from the National Cancer Institute to continue their novel research into therapies that improve the standard of care for patients who develop acute graft-versus-host disease following bone marrow transplantation. [Icahn School of Medicine at Mount Sinai] Press Release | |
| |
POLICY NEWSSafety Concerns Blight Promising Cancer Therapy A groundbreaking treatment that arms immune cells called T cells to battle cancer is barreling towards regulators, fueled by unprecedented clinical success and investor exuberance. [Nature News] Editorial A recruitment and retention program launched by the Howard Hughes Medical Institution in Chevy Chase, Maryland, aims to reduce barriers for women and under-represented minorities who seek academic-research careers in the life sciences. [Nature Careers] Editorial The Many Shades of European Postdoc Funding Finding the right grant or fellowship to fund a postdoc can be a challenge, and the situation is all the more complex in Europe, where academic systems, career prospects, and living costs vary widely among countries. [Science Careers] Editorial
| |
EVENTSNEW TERMIS Americas Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellowship – Gene Regulation and Leukemia (Boston Children’s Hospital) Postdoctoral Fellow – Blood Coagulation and Progenitor Cells (BloodCenter of Wisconsin) Research Associate – Hematology (Editas Medicine) Postdoctoral Associate Position – Blood Cancer and Epigenetic Research (University of Miami) Chair – Medical Biology (Masaryk University) PhD Position – Tumor Microenvironment in Leukemia (Georg-Speyer-Haus) Research Fellow – Cancer Biology (University of Michigan) Assistant Member Faculty – PlatinumImmunotherapy (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|